Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20281021 | 1.00 | HSD17B10 (0.36) | HSD17B10BLMPMP22ALDH1A1KDM4E | |
| SCHEMBL18975548 | 0.99 | HSD17B10 (0.37) | HSD17B10BLMPMP22ALDH1A1KDM4E | |
| SCHEMBL18975194 | 0.97 | HSD17B10 (0.35) | HSD17B10BLMPMP22ALDH1A1KDM4E | |
| SCHEMBL18970210 | 0.96 | HSD17B10 (0.37) | HSD17B10BLMPMP22ALDH1A1KDM4E | |
| SCHEMBL20280995 | 0.96 | HSD17B10 (0.37) | HSD17B10BLMPMP22ALDH1A1KDM4E | |
| SCHEMBL21618561 | 0.96 | HSD17B10 (0.37) | HSD17B10BLMPMP22ALDH1A1KDM4E | |
| SCHEMBL21334345 | 0.95 | HSD17B10 (0.35) | HSD17B10BLMPMP22ALDH1A1KDM4E | |
| SCHEMBL20280869 | 0.94 | KDM4E (0.34) | HSD17B10BLMPMP22ALDH1A1KDM4E | |
| SCHEMBL20280987 | 0.94 | KDM4E (0.34) | HSD17B10BLMPMP22ALDH1A1KDM4E | |
| SCHEMBL20280991 | 0.92 | HSD17B10 (0.33) | HSD17B10BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793533-B2 | Dimeric contrast agents | BRACCO IMAGING S.P.A. (IT) | 2020-10-06 | — | — | US | disclosed |
| US-20200017453-A1 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2020-01-16 | — | — | US | disclosed |
| WO-2018108780-A1 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793533-B2 | Dimeric contrast agents | CALCOCO2, SLC39A14, NOD2 | HSD17B10 4707/4885BLM 2414/4885PMP22 342/4885 |
| US-20200017453-A1 | DIMERIC CONTRAST AGENTS | CALCOCO2, SLC39A14, NOD2 | HSD17B10 4707/4885BLM 2414/4885PMP22 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.